Nicola Gianotti

Summary

Affiliation: San Raffaele Scientific Institute
Country: Italy

Publications

  1. doi request reprint Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy
    N Gianotti
    Department of Infectious Diseases, San Raffalele Scientific Institute, Milan, Italy
    HIV Med 14:153-60. 2013
  2. doi request reprint Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL
    Nicola Gianotti
    Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    J Antimicrob Chemother 67:213-7. 2012
  3. ncbi request reprint In vivo dynamics of the K103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in Human Immunodeficiency Virus-infected patients
    Nicola Gianotti
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    New Microbiol 28:319-26. 2005
  4. doi request reprint No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy
    Nicola Gianotti
    Department of Infectious Diseases, IRCCS San Raffaele, Milan, Italy
    J Med Virol 83:391-8. 2011
  5. ncbi request reprint Redistribution of human immunodeficiency virus type 1 variants resistant to protease inhibitors after a protease inhibitor-sparing regimen
    Nicola Gianotti
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    AIDS Res Hum Retroviruses 21:545-54. 2005
  6. ncbi request reprint Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage study
    Nicola Gianotti
    Clinica di Malattie Infettive, Universita Vita Salute San Raffaele, Milan, Italy
    Clin Infect Dis 42:1470-80. 2006
  7. ncbi request reprint Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir
    Nicola Gianotti
    Clinic of Infectious Diseases, Universita Vita Salute San Raffaele, Milan, Italy
    J Med Virol 78:1537-41. 2006
  8. ncbi request reprint Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir
    Nicola Gianotti
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    New Microbiol 28:119-25. 2005
  9. ncbi request reprint Antiviral activity and clinical efficacy of atazanavir in HIV-1-infected patients: a review
    Nicola Gianotti
    Division of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    New Microbiol 30:79-88. 2007
  10. doi request reprint Detecting impaired glucose tolerance or type 2 diabetes mellitus by means of an oral glucose tolerance test in HIV-infected patients
    N Gianotti
    Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    HIV Med 12:109-17. 2011

Detail Information

Publications54

  1. doi request reprint Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy
    N Gianotti
    Department of Infectious Diseases, San Raffalele Scientific Institute, Milan, Italy
    HIV Med 14:153-60. 2013
    ....
  2. doi request reprint Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL
    Nicola Gianotti
    Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    J Antimicrob Chemother 67:213-7. 2012
    ..It is currently debated whether patients with residual viraemia are at higher risk of virological failure than those attaining <1 HIV RNA copy/mL. We therefore investigated the effect of residual viraemia on virological rebound...
  3. ncbi request reprint In vivo dynamics of the K103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in Human Immunodeficiency Virus-infected patients
    Nicola Gianotti
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    New Microbiol 28:319-26. 2005
    ..This suggests that the K103N mutation per se has little impact on viral fitness in vivo...
  4. doi request reprint No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy
    Nicola Gianotti
    Department of Infectious Diseases, IRCCS San Raffaele, Milan, Italy
    J Med Virol 83:391-8. 2011
    ..145 per 0.1-unit increase, 95% CI=1.093-1.202, P<0.0001), and with earlier calendar years of resistance testing (overall effect: P=0.0007). In conclusion, no pol mutation is associated independently with the lack of immune recovery...
  5. ncbi request reprint Redistribution of human immunodeficiency virus type 1 variants resistant to protease inhibitors after a protease inhibitor-sparing regimen
    Nicola Gianotti
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    AIDS Res Hum Retroviruses 21:545-54. 2005
    ..In highly PI-experienced patients, a PI-sparing regimen may lead to a reduction, no change, or increase in the number of PI mutations. The reduction is negligible in most cases...
  6. ncbi request reprint Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage study
    Nicola Gianotti
    Clinica di Malattie Infettive, Universita Vita Salute San Raffaele, Milan, Italy
    Clin Infect Dis 42:1470-80. 2006
    ..There is still considerable uncertainty as to the best algorithm for interpreting human immunodeficiency virus (HIV) genotyping results...
  7. ncbi request reprint Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir
    Nicola Gianotti
    Clinic of Infectious Diseases, Universita Vita Salute San Raffaele, Milan, Italy
    J Med Virol 78:1537-41. 2006
    ..All of the GIQs were independent predictors of the 48-week virological response. The predictive value of the GIQ for lopinavir/ritonavir may vary depending on the algorithm used to score drug resistance...
  8. ncbi request reprint Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir
    Nicola Gianotti
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    New Microbiol 28:119-25. 2005
    ..In conclusion, the number of ATV resistance mutations is the only correlate to virological response through 24 weeks of treatment with unboosted atazanavir 400 mg once daily...
  9. ncbi request reprint Antiviral activity and clinical efficacy of atazanavir in HIV-1-infected patients: a review
    Nicola Gianotti
    Division of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    New Microbiol 30:79-88. 2007
    ....
  10. doi request reprint Detecting impaired glucose tolerance or type 2 diabetes mellitus by means of an oral glucose tolerance test in HIV-infected patients
    N Gianotti
    Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    HIV Med 12:109-17. 2011
    ....
  11. ncbi request reprint Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy
    Nicola Gianotti
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    J Med Virol 72:181-6. 2004
    ..A sustained virologic response to therapy resumption after treatment interruption can be achieved in the setting of virologic failure. An evaluation of clinical history may help to identify the patients who are more likely to respond...
  12. ncbi request reprint HIV-1 replication capacity and genotype changes in patients undergoing treatment interruption or lamivudine monotherapy
    Nicola Gianotti
    Divisione di Malattie Infettive, Istituto Scientifico San Raffaele, Milan, Italy
    J Med Virol 80:201-8. 2008
    ..The de-selection of the 184V mutation predicts independently a reduction in the CD4+/CD8+ ratio...
  13. ncbi request reprint Leishmania infection can hamper immune recovery in virologically suppressed HIV-infected patients
    Nicola Gianotti
    Division of Infectious Diseases, IRCCS San Raffaele, Milan, Italy
    New Microbiol 31:435-8. 2008
    ..A new drop in CD4+ cell count was observed when Leishmania DNA turned out again to be positive, but treatment with liposomal amphotericin-B restored immune recovery...
  14. ncbi request reprint Sequencing antiretroviral drugs for long-lasting suppression of HIV replication
    Nicola Gianotti
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    New Microbiol 28:281-97. 2005
    ..The optimal timing for starting entry inhibitors during the course of HIV disease has not yet been fully elucidated...
  15. ncbi request reprint Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study)
    Antonella Castagna
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    AIDS 20:795-803. 2006
    ..We compared the immunological and clinical outcomes of lamivudine monotherapy and complete therapy interruption in the treatment of HIV-1-infected patients harbouring lamivudine-resistant virus...
  16. doi request reprint Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir
    Filippo Canducci
    Universita Vita Salute San Raffaele, Milano, Italy
    J Antimicrob Chemother 65:425-33. 2010
    ....
  17. ncbi request reprint The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients
    Nicola Gianotti
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Italy
    J Acquir Immune Defic Syndr 41:447-52. 2006
    ..0001). The multivariable analysis showed that the 118I mutation (P = 0.04) was the only independent genotypic predictor of failing on a stavudine- containing highly active antiretroviral therapy...
  18. ncbi request reprint Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients
    Hamid Hasson
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    AIDS 18:123-7. 2004
    ..Treatment with LPV/r can select for the 50 V mutation. In this setting, significant differences in the inference of the amprenavir phenotype from genotype were observed when using different algorithms...
  19. ncbi request reprint Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients
    Elena Seminari
    Infectious Disease Department, San Raffaele Scientific Institute, Vita Salute University, Via Stamira d Ancona 20, 20122 Milan, Italy
    Eur J Clin Pharmacol 61:545-9. 2005
    ..The aim of this pilot study was to examine the pharmacokinetics of atazanavir (ATV) when given in combination with amprenavir (APV) or saquinavir hard-gel capsules (SQV) to human immunodeficiency virus (HIV)-positive patients...
  20. ncbi request reprint The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen
    Antonella Castagna
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    Antivir Ther 9:537-43. 2004
    ..To investigate the normalized inhibitory quotient (NIQ) of lopinavir (LPV) as a predictor of 48-week virological responses to a lopinavir/ritonavir (LPV/RTV)-containing regimen in highly treatment-experienced patients...
  21. doi request reprint Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1-infected multidrug-resistant patients
    Vincenzo Spagnuolo
    Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    J Acquir Immune Defic Syndr 50:192-5. 2009
    ..To evaluate changes in resistance to tipranavir/r (TPV/r) and darunavir/r (DRV/r) in patients who had failed a TPV/r-including regimen...
  22. ncbi request reprint Boosted or unboosted atazanavir as a simplification of lopinavir/ritonavir-containing regimens
    Antonella Castagna
    Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    New Microbiol 36:239-49. 2013
    ....
  23. ncbi request reprint Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients
    Nicola Gianotti
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    AIDS 18:2205-8. 2004
    ..After a median of 26 weeks of treatment, two patients (10%) selected the 65R mutation. These results support the hypothesis that NEM hinder the selection of this mutation...
  24. doi request reprint Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice
    Mattia C F Prosperi
    Clinic of Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    J Med Virol 82:1996-2003. 2010
    ..Despite the likely differences in patient population and adherence, both the low rate of virological failure and the lack of development of LPV/rtv resistance documented in clinical trials are thus confirmed in clinical practice...
  25. doi request reprint Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART
    Annalisa Saracino
    Clinic of Infectious Diseases, University of Foggia, Foggia, Italy
    J Med Virol 80:1695-706. 2008
    ..Therefore, in some cases DNA plus RNA genotyping might assist in choosing more accurately subsequent antiretroviral regimens...
  26. ncbi request reprint Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients
    Monica Guffanti
    Department of Infectious Diseases, Vita Salute University, San Raffaele Scientific Institute, Milan, Italy
    AIDS 17:2669-71. 2003
    ..Our preliminary results suggest that amprenavir and atazanavir could be coadministered and that amprenavir could be boosted by atazanavir without the need for ritonavir pharmaco-enhancement...
  27. doi request reprint Survival of HIV-1 infected multidrug-resistant patients recycling enfuvirtide after a previous failure
    Francesca Cossarini
    Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    J Acquir Immune Defic Syndr 51:179-84. 2009
    ..We evaluated long-term survival in multidrug-resistant patients recycling ENF after a previous failure...
  28. doi request reprint Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies
    Filippo Canducci
    Universita Vita Salute San Raffaele, Italy
    AIDS 23:455-60. 2009
    ..Evaluate HIV-1 subtype B integrase gene evolution in patients failing raltegravir (RAL)-based savage regimens by clonal analysis of the replicating viral quasispecies...
  29. ncbi request reprint Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial
    Francesco Mazzotta
    Department of Infectious Diseases, S M Annunziata Hospital, ASL Firenze, Italy
    J Acquir Immune Defic Syndr 32:268-80. 2003
    ..Several factors should be considered to take better advantage of resistance testing, including treatment history, clinical status, and patients' ability to adhere to treatment...
  30. doi request reprint Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience
    Silvia Nozza
    Department of Infectious Diseases, San Raffaele Scientific Institute, Italy
    AIDS 24:924-8. 2010
    ..Although long-term safety needs further study, this protease inhibitor and nucleoside analogue-sparing regimen showed sustained efficacy...
  31. doi request reprint Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy
    Antonella Castagna
    Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy
    Antivir Ther 15:165-75. 2010
    ..The extent of short-term CD4(+) T-cell recovery in patients tolerating first-line highly active antiretroviral therapy (HAART) and attaining undetectable HIV RNA levels is inadequately defined...
  32. doi request reprint Immune recovery and T cell subset analysis during effective treatment with maraviroc
    Francesca Cossarini
    Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    J Antimicrob Chemother 67:2474-8. 2012
    ..Patients treated with maraviroc frequently show high CD4+ T cell increases. The aim of this study was to detail the characteristics of maraviroc-induced immune recovery...
  33. ncbi request reprint Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir
    Nicola Gianotti
    Divisione di Malattie Infettive, Istituto Scientifico San Raffaele, Milan, Italy
    AIDS 21:1648-51. 2007
    ..The electrocardiographic monitoring of patients treated with atazanavir seems advisable...
  34. doi request reprint Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancer-free, HIV-1-infected patients: a matched cohort study
    Vincenzo Spagnuolo
    Infectious Disease Department, San Raffaele Scientific Institute, Milan, Italy
    Cancer 119:2710-9. 2013
    ....
  35. doi request reprint Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy
    Laura Galli
    Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    Eur J Epidemiol 27:657-65. 2012
    ....
  36. doi request reprint Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies
    Vincenzo Spagnuolo
    Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy
    Int J Cancer 130:2990-6. 2012
    ..5% ± 14.5% vs. 40.0% ± 12.7%; log-rank test: p = 0.005). Despite the better cancer prognosis during the post-HAART era, the 10-year survival of HIV-infected subjects with an ADM or NADM is poor...
  37. ncbi request reprint Favorable outcome of ex-vivo purging of monocytes after the reintroduction of treatment after interruption in patients infected with multidrug resistant HIV-1
    Hamid Hasson
    San Raffaele Scientific Institute, Infectious Diseases Clinic, Milano, Italy
    J Med Virol 79:1640-9. 2007
    ..021). A consistent decrease of HIV DNA load in CD14+ purified cells was observed only in treatment interruption + MYP patients. These data suggest that MYP can improve the immunological and virological response to treatment interruption...
  38. ncbi request reprint Management of HIV infection after triple class failure
    Francesca Cossarini
    Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    New Microbiol 36:23-39. 2013
    ....
  39. ncbi request reprint Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine
    Monica Guffanti
    Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    Am J Trop Med Hyg 79:715-8. 2008
    ..The skin lesions did not recover after treatment with oral miltefosine at 100 mg/day for five cycles of 28 days but responded to treatment with liposomal amphotericin B...
  40. doi request reprint Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study
    Mattia C F Prosperi
    Clinic of Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    J Antimicrob Chemother 66:1886-96. 2011
    ....
  41. ncbi request reprint Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients
    Alessandro Soria
    Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    Antivir Ther 14:339-47. 2009
    ..We investigated the factors associated with resistance after the initiation of antiretroviral therapy (ART) in the absence of virological monitoring...
  42. doi request reprint Mortality of HIV-infected patients with or without cancer: comparison with the general population in Italy
    Laura Galli
    Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    Antivir Ther 17:447-58. 2012
    ..HAART has reduced mortality in HIV-infected patients; however, the risk of non-AIDS-related events has increased, including cancer. We compared mortality in HIV-infected patients with or without cancer with the general population in Italy...
  43. ncbi request reprint Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens
    Alba Bigoloni
    aDepartment of Infectious Diseases, San Raffaele Scientific Institute bUniversità Vita Salute San Raffaele cCardiometabolic and Clinical Trials Unit, Metabolic and Cardiovascular Division, Internal Medicine Department, San Raffaele Scientific Institute, Milan, Italy
    AIDS 26:1837-40. 2012
    ..A worsening glucose tolerance was observed in highly treatment-experienced HIV-infected patients receiving effective antiretroviral therapy after virological failure...
  44. doi request reprint Optimal dietary calcium intake in HIV treated patients: No femoral osteoporosis but higher cardiovascular risk
    Laura Galli
    Department of Infectious Diseases, San Raffaele Scientific Institute, Via Stamira d Ancona 20, 20127 Milan, Italy Electronic address
    Clin Nutr 33:363-6. 2014
    ....
  45. doi request reprint A novel methodology for large-scale phylogeny partition
    Mattia C F Prosperi
    Clinic of Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    Nat Commun 2:321. 2011
    ..Our method takes an advantage of a flexible notion of transmission cluster and can become a general framework to analyse other epidemics...
  46. ncbi request reprint Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment
    Elena Seminari
    Infectious Disease Department, San Raffaele Scientific Institute and Universita Vita Salute San Raffaele, Via Stamina d Ancona 20, 20122 Milan, Italy
    J Antimicrob Chemother 60:831-6. 2007
    ..The purpose of this study was to evaluate the steady-state pharmacokinetics of amprenavir and ritonavir in HIV-infected patients with different degrees of hepatic impairment...
  47. ncbi request reprint Evolutionary characteristics of HIV type 1 variants resistant to protease inhibitors in the absence of drug-selective pressure
    Enzo Boeri
    Diagnostica and Ricerca San Raffaele, Laoratorio di Virologia, Centro San Luigi, I R C C S Istituto Scientifico San Raffaele, 20 20127 Milan, Italy
    AIDS Res Hum Retroviruses 19:1151-3. 2003
    ....
  48. ncbi request reprint Tumor necrosis factor alpha, interleukin 2, and soluble interleukin 2 receptor levels in human immunodeficiency virus type 1-infected individuals receiving intermittent cycles of interleukin 2
    Claudio Fortis
    Division of Infectious Diseases, San Raffaele Scientific Institute, 20127 Milan, Italy
    AIDS Res Hum Retroviruses 18:491-9. 2002
    ..The latter was correlated to the peak serum level of IL-2, but not to those of TNF-alpha and IL-6...
  49. ncbi request reprint Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients: 24-week immunological outcome
    Nicola Gianotti
    AIDS 18:821-3. 2004
  50. ncbi request reprint Lack of reduction of thymidine kinase activity in stavudine-treated HIV-infected patients
    Ombretta Turriziani
    Department of Experimental Medicine and Pathology Virology Section, University La Sapienza, 00185 Rome, Italy
    AIDS Res Hum Retroviruses 20:701-3. 2004
    ....
  51. ncbi request reprint Determinants of HIV-1 genotypic resistance to darunavir (TMC114) in a large Italian resistance database (Antiretroviral Resistance Cohort Analysis)
    Stefano Rusconi
    J Acquir Immune Defic Syndr 46:373-5. 2007
  52. doi request reprint Expression levels of MDR1, MRP1, MRP4, and MRP5 in peripheral blood mononuclear cells from HIV infected patients failing antiretroviral therapy
    Ombretta Turriziani
    Department of Experimental Medicine, Virology Section, Sapienza, University of Rome, Rome, Italy
    J Med Virol 80:766-71. 2008
    ..The expression of MRP4 and MRP5 seems to correlate with CD4 cell counts. The same protein seems to be overexpressed in patients receiving NNRTIs...
  53. ncbi request reprint Thymidine kinase and deoxycytidine kinase activity in mononuclear cells from antiretroviral-naive HIV-infected patients
    Ombretta Turriziani
    Department of Experimental Medicine and Pathology, Virology Section, University La Sapienza, 28 00185 Rome, Italy
    AIDS 19:473-9. 2005
    ....
  54. ncbi request reprint Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation
    Andrea Antinori
    National Institute for Infectious Diseases L Spallanzani IRCCS, Roma, Italy
    Antivir Ther 12:1175-83. 2007
    ..The effect of the HIV reverse transcriptase K65R mutation on virological response to salvage therapy has not been clearly defined...